ABSTRACT
Many biological products are under investigation for the treatment of rheumatoid arthritis (RA). The number of agents that will be evaluated is to increase considerably in the next few years. The agents vary from monoclonal antibodies to cell receptors such as CD4, cytokines such as TNF-a:, and recombinant products such as IL-I receptor antagonist. Other classes of biological products will eventually be evaluated for their therapeutic potential. This evaluation requires defined standards for clinical trials and determining efficacy of these agents.
